A method of separation of antibodies by affinity chromatography, which method comprises the steps of: a) conveying a process feed, optionally comprising at least 4 mg/ml antibodies, through at least a first chromatography column, to adsorb antibodies from said feed, and passing an effluent from said first chromatography column through a second chromatography column packed with the same separation matrix as the first column; a') after step a), redirecting the process feed to the second chromatography column and passing an effluent from the second chromatography column through a third chromatography column packed with the same separation matrix as the second column; b) optionally washing said first chromatography column; c) conveying an eluent through said first chromatography column to elute antibodies; a"), after step a') and step c), redirecting the process feed to the third chromatography column and passing an effluent from the third chromatography column through the first chromatography column; c'), after step a'), conveying the eluent through the second chromatography column to elute antibodies; c"), after step a"), conveying the eluent through the third chromatography column to elute antibodies; and d) recovering said eluent with antibodies, wherein: the sequence of steps a), a'), a"), c), c') and c") is optionally repeated one or more times; said first column comprises a packed bed of a separation matrix, with a bed height of 2-5 cm, and; i) said separation matrix comprises porous spherical particles to which antibody-binding protein ligands have been covalently immobilized; ii) the density of said ligands is above 10 mg/ml; iii) the volume-weighted median diameter of said particles is in the range of 30 - 55 μm; and iv) said porous spherical particles comprise a crosslinked polysaccharide and have a gel phase distribution coefficient, expressed as K D for dextran of molecular weight 110 kDa, of 0.6-0.8. a) conveying a process feed, optionally comprising at least 4 mg/ml antibodies, through at least a first chromatography column, to adsorb antibodies from said feed, and passing an effluent from said first chromatography column through a second chromatography column packed with the same separation matrix as the first column; a') after step a), redirecting the process feed to the second chromatography column and passing an effluent from the second chromatography column through a third chromatography column packed with the same separation matrix as the second column; b) optionally washing said first chromatography column; c) conveying an eluent through said first chromatography column to elute antibodies; a"), after step a') and step c), redirecting the process feed to the third chromatography column and passing an effluent from the third chromatography column through the first chromatography column; c'), after step a'), conveying the eluent through the second chromatography column to elute antibodies; c"), after step a"), conveying the eluent through the third chromatography column to elute antibodies; and a"), after step a') and step c), redirecting the process feed to the third chromatography column and passing an effluent from the third chromatography column through the first chromatography column; c'), after step a'), conveying the eluent through the second chromatography column to elute antibodies; c"), after step a"), conveying the eluent through the third chromatography column to elute antibodies; and d) recovering said eluent with antibodies, wherein: the sequence of steps a), a'), a"), c), c') and c") is optionally repeated one or more times; said first column comprises a packed bed of a separation matrix, with a bed height of 2-5 cm, and; i) said separation matrix comprises porous spherical particles to which antibody-binding protein ligands have been covalently immobilized; ii) the density of said ligands is above 10 mg/ml; iii) the volume-weighted median diameter of said particles is in the range of 30 - 55 μm; and iv) said porous spherical particles comprise a crosslinked polysaccharide and have a gel phase distribution coefficient, expressed as K D for dextran of molecular weight 110 kDa, of 0.6-0.8. the sequence of steps a), a'), a"), c), c') and c") is optionally repeated one or more times; said first column comprises a packed bed of a separation matrix, with a bed height of 2-5 cm, and; i) said separation matrix comprises porous spherical particles to which antibody-binding protein ligands have been covalently immobilized; ii) the density of said ligands is above 10 mg/ml; iii) the volume-weighted median diameter of said particles is in the range of 30 - 55 μm; and iv) said porous spherical particles comprise a crosslinked polysaccharide and have a gel phase distribution coefficient, expressed as K D for dextran of molecular weight 110 kDa, of 0.6-0.8. i) said separation matrix comprises porous spherical particles to which antibody-binding protein ligands have been covalently immobilized; ii) the density of said ligands is above 10 mg/ml; iii) the volume-weighted median diameter of said particles is in the range of 30 - 55 μm; and iv) said porous spherical particles comprise a crosslinked polysaccharide and have a gel phase distribution coefficient, expressed as K D for dextran of molecular weight 110 kDa, of 0.6-0.8.